WO2000039302A3 - Improved expression of hiv polypeptides and production of virus-like particles - Google Patents
Improved expression of hiv polypeptides and production of virus-like particles Download PDFInfo
- Publication number
- WO2000039302A3 WO2000039302A3 PCT/US1999/031245 US9931245W WO0039302A3 WO 2000039302 A3 WO2000039302 A3 WO 2000039302A3 US 9931245 W US9931245 W US 9931245W WO 0039302 A3 WO0039302 A3 WO 0039302A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vlps
- particles
- production
- virus
- polypeptides
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 239000002245 particle Substances 0.000 title abstract 2
- 241000238631 Hexapoda Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 230000027317 positive regulation of immune response Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU22216/00A AU2221600A (en) | 1998-12-31 | 1999-12-30 | Improved expression of hiv polypeptides and production of virus-like particles |
CA2360347A CA2360347C (en) | 1998-12-31 | 1999-12-30 | Improved expression of hiv polypeptides and production of virus-like particles |
JP2000591193A JP2002533124A (en) | 1998-12-31 | 1999-12-30 | Improved expression of HIV polypeptide and generation of virus-like particles |
EP99966727A EP1141313A2 (en) | 1998-12-31 | 1999-12-30 | Improved expression of hiv polypeptides and production of virus-like particles |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11449598P | 1998-12-31 | 1998-12-31 | |
US60/114,495 | 1998-12-31 | ||
US16847199P | 1999-12-01 | 1999-12-01 | |
US60/168,471 | 1999-12-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000039302A2 WO2000039302A2 (en) | 2000-07-06 |
WO2000039302A3 true WO2000039302A3 (en) | 2001-01-04 |
Family
ID=26812261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/031245 WO2000039302A2 (en) | 1998-12-31 | 1999-12-30 | Improved expression of hiv polypeptides and production of virus-like particles |
Country Status (6)
Country | Link |
---|---|
US (5) | US6602705B1 (en) |
EP (3) | EP2206785A1 (en) |
JP (3) | JP2002533124A (en) |
AU (1) | AU2221600A (en) |
CA (1) | CA2360347C (en) |
WO (1) | WO2000039302A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9598469B2 (en) | 2001-07-05 | 2017-03-21 | Novartis Vaccines And Diagnostics, Inc. | HIV-1 south african subtype C env proteins |
Families Citing this family (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020173643A1 (en) * | 1995-04-14 | 2002-11-21 | Kappes John C. | Fusion protein delivery system and uses thereof |
WO1998012332A1 (en) | 1996-09-17 | 1998-03-26 | Chiron Corporation | Compositions and methods for treating intracellular diseases |
GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
US7622300B2 (en) * | 1998-06-03 | 2009-11-24 | Kappes John C | Trans-lentiviral vector particles and transduction of eukaryotic cells therewith |
US6555342B1 (en) | 1998-06-03 | 2003-04-29 | Uab Research Foundation | Fusion protein delivery system and uses thereof |
CA2358385C (en) | 1998-12-31 | 2013-08-06 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
US20030194800A1 (en) * | 2001-08-31 | 2003-10-16 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
PL351988A1 (en) * | 1999-04-26 | 2003-07-14 | Leuven K U Res & Dev | Synthetic gene for expressing active retroviral protein in eukaryotes |
AU777120B2 (en) * | 1999-06-11 | 2004-09-30 | Medigene, Inc. | Use of viral vectors and charged molecules for gene therapy |
US6710173B1 (en) * | 1999-06-25 | 2004-03-23 | Progenics Pharmaceuticals, Inc. | Stabilized viral envelope proteins and uses thereof |
ATE391785T1 (en) * | 1999-11-16 | 2008-04-15 | Geneart Ag | THE HIV-1 INTERSUBTYPE (C/B') GENOME AND ITS APPLICATIONS |
ES2329648T3 (en) * | 1999-12-23 | 2009-11-30 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | MOLECULAR CLONES WITH MUTED GENES HIV GAG / POL, VIS GAG AND VIS VIS. |
US6656706B2 (en) | 1999-12-23 | 2003-12-02 | The United States Of America As Represented By The Department Of Health And Human Services | Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes |
CN1248740C (en) | 2000-03-30 | 2006-04-05 | 株式会社载体研究所 | AIDS virus vaccine with use of sendai virus vector |
GB0009760D0 (en) * | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
US7094882B2 (en) | 2000-04-21 | 2006-08-22 | Yeda Research And Development Co. Ltd. | Growth factor which acts through erb b-4 rtk |
US6783939B2 (en) | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
AU2001276752A1 (en) * | 2000-08-08 | 2002-02-18 | The Kitasato Institute | Virus-like micrograins and process for producing the same |
JP5052732B2 (en) | 2000-08-14 | 2012-10-17 | アメリカ合衆国 | Modification of HIV Env, Gag, and Pol to enhance immunogenicity for genetic immunization |
US6582920B2 (en) * | 2000-09-01 | 2003-06-24 | Gen-Probe Incorporated | Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations |
AU2001294562B2 (en) * | 2000-09-15 | 2007-05-24 | Merck & Co., Inc. | Enhanced First Generation Adenovirus Vaccines Expressing Codon Optimized HIV1-Gag, Pol, Nef and Modifications |
CN1468089B (en) * | 2000-09-28 | 2011-09-21 | 诺华疫苗和诊断公司 | Microparticles for delivery of the heterologous nucleic acids |
WO2002039951A2 (en) * | 2000-11-15 | 2002-05-23 | Globe Immune, Inc. | Yeast-dentritic cell vaccines and uses thereof |
US20040161846A1 (en) * | 2000-11-22 | 2004-08-19 | Mason Anthony John | Method of expression and agents identified thereby |
DE60239317D1 (en) | 2001-01-12 | 2011-04-14 | Novartis Vaccines & Diagnostic | NUCLEIC ACID MUCOSAL IMMUNIZATION |
EP1421222A4 (en) * | 2001-03-09 | 2004-07-07 | Univ California | Cell culture system for synthesis of infectious hepatitis c virus |
US20060222656A1 (en) * | 2005-04-01 | 2006-10-05 | University Of Maryland, Baltimore | MAGE-A3/HPV 16 peptide vaccines for head and neck cancer |
WO2002094994A2 (en) * | 2001-05-18 | 2002-11-28 | Mayo Foundation For Medical Education And Research | Chimeric antigen-specific t cell-activating polypeptides |
EP1832603B1 (en) | 2001-06-05 | 2010-02-03 | CureVac GmbH | Stabilised mRNA with increased G/C-content encoding a bacterial antigen and its use |
US20030198621A1 (en) | 2001-07-05 | 2003-10-23 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof |
US20030170614A1 (en) * | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
JP4790984B2 (en) | 2001-09-06 | 2011-10-12 | アルファヴァックス,インコーポレイテッド | Alphavirus replicon vector system |
ATE519500T1 (en) * | 2001-09-06 | 2011-08-15 | Progenics Pharm Inc | MUTANTS OF ENVELOPE GLYCOPROTEINS OF THE HUMAN IMMUNODEFICIENCY VIRUS AND THEIR USE |
EP2322626A1 (en) * | 2001-09-20 | 2011-05-18 | Glaxo Group Limited | HIV-GAG codon-optimised DNA vaccines |
AR045702A1 (en) | 2001-10-03 | 2005-11-09 | Chiron Corp | COMPOSITIONS OF ASSISTANTS. |
WO2003068925A2 (en) * | 2002-02-11 | 2003-08-21 | Mosca Joseph D | Production of a protein delivery system for in vivo therapeutic treatment |
US20040040061A1 (en) * | 2002-02-27 | 2004-02-26 | Michael Horn | Expression in plants of HIV-related proteins |
US20060051373A1 (en) * | 2002-04-05 | 2006-03-09 | Olson William C | Particle-bound human immunodeficiency virus envelope glycoproteins and related compositions and methods |
BR0308896A (en) | 2002-05-07 | 2007-01-09 | Chiron Corp | hiv-cd4 envelope complex and hybrid |
US9045727B2 (en) * | 2002-05-17 | 2015-06-02 | Emory University | Virus-like particles, methods of preparation, and immunogenic compositions |
WO2004042001A2 (en) * | 2002-05-17 | 2004-05-21 | Emory University | Virus-like particles, methods of preparation, and immonogenic compositions |
US8025873B2 (en) * | 2002-06-20 | 2011-09-27 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
AU2003258388C1 (en) * | 2002-09-13 | 2010-03-18 | The University Of Queensland | Gene expression system based on codon translation efficiency |
JP2006502228A (en) | 2002-10-07 | 2006-01-19 | カイロン コーポレイション | HIV vaccine formulation |
CA2504938C (en) * | 2002-11-07 | 2011-10-11 | Synergy America, Inc. | Compositions and methods for treating or preventing pneumococcal infection |
AU2003294297A1 (en) * | 2002-11-15 | 2004-06-15 | The Henry M. Jackson Foundation | Recombinant hiv-1 subclass d envelope glycoproteins |
CN1745095A (en) * | 2002-12-04 | 2006-03-08 | 开普敦大学 | A method for the production of HIV-1 GAG virus-like particles |
KR101454842B1 (en) | 2003-03-20 | 2014-11-04 | 알파벡스, 인크. | Improved alphavirus replicons and helper constructs |
KR20050110709A (en) * | 2003-04-07 | 2005-11-23 | 코닌클리즈케 필립스 일렉트로닉스 엔.브이. | Display device |
US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
MXPA05012270A (en) * | 2003-05-12 | 2006-02-10 | Univ Florida | Materials and methods for immunizing against fiv infection. |
US7658927B2 (en) * | 2003-05-12 | 2010-02-09 | University Of Florida Research Foundation, Inc. | Materials and methods for immunizing against FIV infection |
WO2005007808A2 (en) * | 2003-05-15 | 2005-01-27 | Chiron Corporation | Hiv polynucleotides and polypeptides derived from botswana mj4 |
ATE432285T1 (en) | 2003-07-11 | 2009-06-15 | Alphavax Inc | CYTOMEGALOVIRUS VACCINES BASED ON ALPHAVIRUS |
US7320795B2 (en) * | 2003-07-30 | 2008-01-22 | Vaccine Research Institute Of San Diego | Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof |
US7144712B2 (en) * | 2003-07-30 | 2006-12-05 | Vaccine Research Institute Of San Diego | Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof |
WO2005011571A2 (en) | 2003-07-30 | 2005-02-10 | Vaccine Research Institute Of San Diego | Hepatitis virus core proteins as vaccine platforms and methods of use thereof |
CA2539021A1 (en) * | 2003-09-15 | 2005-03-31 | Chiron Corporation | Combination approaches for generating immune responses |
WO2005062871A2 (en) * | 2003-12-19 | 2005-07-14 | University Of Maryland Biotechnology Institute | Tat linear epitope peptides and conjugates thereof for use in therapeutic compositions and assays |
ES2307345B1 (en) * | 2004-01-21 | 2009-11-13 | Consejo Sup. Investig. Cientificas | CHEMICAL EMPTY CAPSIDES OF THE VIRUS CAUSING THE INFECTIOUS BURSITIS DISEASE (IBDV), ITS PROCEDURE FOR OBTAINING AND APPLICATIONS. |
ES2307346B1 (en) * | 2004-01-21 | 2009-11-13 | Consejo Sup. Investig. Cientificas | EMPTY CAPSIDES (VLPS (-VP4)) OF THE VIRUS CAUSING THE INFECTIOUS BURSITIS DISEASE (IBDV), ITS PROCESSING PROCEDURE AND APPLICATIONS. |
US7622125B2 (en) | 2004-05-05 | 2009-11-24 | Novartis Vaccines And Diagnostics, Inc. | Polycistronic HIV vector constructs |
WO2006085959A2 (en) | 2004-06-08 | 2006-08-17 | Novartis Vaccines And Diagnostics Inc. | Fusion proteins comprising cd4 minimal modules and methods of use thereof |
US20080274134A1 (en) * | 2004-06-15 | 2008-11-06 | Norbert Schulke | Hiv-1 Neutralizing Antibodies Elicited By Trimeric Hiv-1 Envelope Glycoprotein Complex |
CA2585672A1 (en) * | 2004-11-01 | 2006-05-11 | Novartis Vaccines And Diagnostics Inc. | Combination approaches for generating immune responses |
CA2597040A1 (en) | 2005-02-03 | 2006-08-10 | Novartis Vaccines And Diagnostics, Inc. | Hiv tat-cd4 hybrid molecules and methods of use thereof |
ES2310062B1 (en) * | 2005-07-15 | 2009-11-13 | Bionostra, S.L. | PSEUDOVIRAL PARTICLES CHEMICAL EMPTY DERIVED FROM VIRUS CAUSING INFECTIOUS BURSITIS DISEASE (IBDV), PROCEDURE OF OBTAINING AND APPLICATIONS. |
US7951384B2 (en) * | 2005-08-05 | 2011-05-31 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
US9216212B2 (en) | 2005-08-05 | 2015-12-22 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
WO2007047749A1 (en) | 2005-10-18 | 2007-04-26 | Novartis Vaccines And Diagnostics Inc. | Mucosal and systemic immunizations with alphavirus replicon particles |
WO2007084568A2 (en) | 2006-01-17 | 2007-07-26 | Health Research, Inc. | Heteroduplex tracking assay |
EP2382988A1 (en) | 2006-03-31 | 2011-11-02 | Novartis AG | Combined mucosal and parenteral immunization against HIV |
US20110076298A1 (en) * | 2006-06-19 | 2011-03-31 | Olson William C | Soluble stabilized trimeric hiv env proteins and uses thereof |
CA2657626C (en) | 2006-07-13 | 2020-02-25 | Institute For Advanced Study | Viral inhibitory nucleotide sequences and vaccines |
WO2008094197A2 (en) * | 2006-07-27 | 2008-08-07 | Ligocyte Pharmaceuticals, Inc. | Chimeric influenza virus-like particles |
WO2008063331A2 (en) * | 2006-10-23 | 2008-05-29 | Progenics Pharmaceuticals, Inc. | Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof |
US8617816B2 (en) * | 2007-03-16 | 2013-12-31 | 454 Life Sciences, A Roche Company | System and method for detection of HIV drug resistant variants |
CN101802199B (en) | 2007-06-21 | 2012-08-22 | 阿尔法瓦克斯公司 | Promoterless cassettes for expression of alphavirus structural proteins |
US8815253B2 (en) | 2007-12-07 | 2014-08-26 | Novartis Ag | Compositions for inducing immune responses |
GB0802224D0 (en) * | 2008-02-06 | 2008-03-12 | Inst Superiore Di Sanito | Process for the production of vaccine components |
WO2009111304A2 (en) * | 2008-02-29 | 2009-09-11 | President And Fellows Of Harvard College | A fusion-intermediate state of hiv-1 gp41 targeted by broadly neutralizing antibodies |
WO2011106705A2 (en) | 2010-02-26 | 2011-09-01 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Dna-protein vaccination protocols |
AU2011230619C1 (en) | 2010-03-25 | 2016-06-23 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
HUE047796T2 (en) | 2010-07-06 | 2020-05-28 | Glaxosmithkline Biologicals Sa | Delivery of rna to trigger multiple immune pathways |
US10487332B2 (en) | 2010-07-06 | 2019-11-26 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of RNA |
US20130171241A1 (en) | 2010-07-06 | 2013-07-04 | Novartis Ag | Liposomes with lipids having an advantageous pka-value for rna delivery |
US20120121633A1 (en) * | 2010-07-16 | 2012-05-17 | Sudhir Paul | Hiv cd4 binding site based covalent immunogen compositions |
SI3970742T1 (en) | 2010-08-31 | 2022-08-31 | Glaxosmithkline Biologicals S.A. | Pegylated liposomes for delivery of immunogen-encoding rna |
MX363307B (en) | 2010-10-11 | 2019-03-20 | Novartis Ag Star | Antigen delivery platforms. |
EP2633047A4 (en) | 2010-10-25 | 2014-04-02 | Philadelphia Children Hospital | Compositions and methods for the generation of platelets and methods of use thereof |
TWI526539B (en) * | 2010-12-22 | 2016-03-21 | 苜蓿股份有限公司 | Method of producing virus-like particles (vlps) in plants and vlp produced by such method |
LT2691530T (en) | 2011-06-10 | 2018-08-10 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
CA2840989A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
US10150970B2 (en) | 2011-07-27 | 2018-12-11 | Applied Biotechnology Institute, Inc. | Methods to increase antigenicity of membrane-bound polypeptides produced in plants |
AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
MX2014005548A (en) | 2011-11-14 | 2014-08-21 | Novartis Ag | Immunogenic complexes of polyanionic carbomers and env polypeptides and methods of manufacture and use thereof. |
EP2790737B1 (en) * | 2011-12-12 | 2018-11-21 | The Children's Hospital of Philadelphia | Large commercial scale lentiviral vector production system and vectors produced thereby |
ES2631608T3 (en) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Env-glycoprotein variant of HIV-1 |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
EP3122881A4 (en) * | 2014-03-25 | 2017-11-15 | Duke University | Mosaic hiv-1 sequences and uses thereof |
GB2526339A (en) * | 2014-05-21 | 2015-11-25 | Imp Innovations Ltd | Lentiviral vectors |
US9944679B2 (en) | 2015-03-16 | 2018-04-17 | The Catholic University Of America | Authentic trimeric HIV-1 envelope glycoproteins comprising a long linker and tag |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
WO2017068077A1 (en) * | 2015-10-20 | 2017-04-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods and products for genetic engineering |
AU2017332854A1 (en) | 2016-09-21 | 2019-04-11 | The Governors Of The University Of Alberta | Hepatitis C virus immunogenic compositions and methods of use thereof |
US20220194990A1 (en) * | 2019-01-31 | 2022-06-23 | Board Of Regents Of The University Of Nebraska | Virus-like particles and methods of use thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997031115A2 (en) * | 1996-02-22 | 1997-08-28 | Merck & Co., Inc. | Synthetic hiv genes |
WO1998012207A1 (en) * | 1996-09-20 | 1998-03-26 | The General Hospital Corporation | High level expression of proteins |
WO1998034640A2 (en) * | 1997-02-07 | 1998-08-13 | Merck & Co., Inc. | Synthetic hiv gag genes |
WO1999041397A1 (en) * | 1998-02-17 | 1999-08-19 | Oxford Biomedica (Uk) Limited | Anti-viral vectors |
WO2000015819A1 (en) * | 1998-09-11 | 2000-03-23 | The Children's Medical Center Corporation | Packaging cell lines for hiv-derived retroviral vector particles |
Family Cites Families (186)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5326859A (en) | 1979-10-30 | 1994-07-05 | Juridical Foundation, Japanese Foundation For Cancer Research | DNA and recombinant plasmid |
US4405712A (en) | 1981-07-01 | 1983-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | LTR-Vectors |
AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
US5364773A (en) | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
EP0091539B2 (en) | 1982-03-31 | 1996-11-27 | Ajinomoto Co., Inc. | Gene coding for interleukin-2 polypeptide, recombinant DNA carrying said gene, cell lines possessing the recombinant DNA,and method for producing interleukin-2 using said cells |
US4652639A (en) | 1982-05-06 | 1987-03-24 | Amgen | Manufacture and expression of structural genes |
US4853332A (en) | 1982-10-19 | 1989-08-01 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins |
US4966843A (en) | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
US4876197A (en) | 1983-02-22 | 1989-10-24 | Chiron Corporation | Eukaryotic regulatable transcription |
US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
ATE220101T1 (en) | 1983-04-25 | 2002-07-15 | Chiron Corp | HYBRID DNA SYNTHESIS OF MATURE INSULIN-LIKE GROWTH FACTORS |
US4892743A (en) | 1983-12-21 | 1990-01-09 | Schering Corporation | Novel hybrid interferon species |
WO1985002862A1 (en) | 1983-12-23 | 1985-07-04 | Monash University | PRODUCTION OF HUMAN INTERFERON-alpha |
US5464774A (en) | 1984-03-05 | 1995-11-07 | The Salk Institute For Biological Studies | Bovine basic fibroblast growth factor |
US5155214A (en) | 1984-03-05 | 1992-10-13 | The Salk Institute For Biological Studies | Basic fibroblast growth factor |
AU594014B2 (en) | 1984-03-21 | 1990-03-01 | Research Corporation Technologies, Inc. | Recombinant DNA molecules |
US5171568A (en) | 1984-04-06 | 1992-12-15 | Chiron Corporation | Recombinant herpes simplex gb-gd vaccine |
US6610476B1 (en) | 1984-08-22 | 2003-08-26 | The United States Of America As Represented By The Department Of Health And Human Services | Detection of HIV-1 DNA |
US4722840A (en) | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
US5032510A (en) | 1984-09-26 | 1991-07-16 | Eli Lilly And Company | Method for expression and secretion in bacillus |
CA1341482C (en) | 1984-10-31 | 2005-05-10 | Paul A. Luciw | Process for preparing fragments of aids-associated retroviruses |
US5100792A (en) | 1984-11-13 | 1992-03-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues |
US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
EP0203177A4 (en) | 1984-11-29 | 1987-04-28 | Scripps Clinic Res | Polypeptides and antibodies related to deglycosylated viral glycoproteins. |
AU600658B2 (en) | 1984-12-24 | 1990-08-23 | Genentech Inc. | Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use |
US4847201A (en) | 1985-02-05 | 1989-07-11 | Cetus Corporation | DNA encoding for CSF-1 and accompanying recombinant systems |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
NZ215867A (en) | 1985-04-19 | 1989-10-27 | Hoffmann La Roche | Aids envelope protein, dna vectors and method of production |
US4663161A (en) | 1985-04-22 | 1987-05-05 | Mannino Raphael J | Liposome methods and compositions |
US4871488A (en) | 1985-04-22 | 1989-10-03 | Albany Medical College Of Union University | Reconstituting viral glycoproteins into large phospholipid vesicles |
US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
JPS63500636A (en) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | DNA encoding multipotent granulocyte colony stimulating factor |
US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
ATE108022T1 (en) | 1985-10-24 | 1994-07-15 | Southwest Found Biomed Res | SYNTHETIC PEPTIDES AND THEIR USE IN DIAGNOSIS AND VACCINATION FOR AIDS AND ARC. |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5017691A (en) | 1986-07-03 | 1991-05-21 | Schering Corporation | Mammalian interleukin-4 |
US4994559A (en) | 1985-12-17 | 1991-02-19 | Synergen, Inc. | Human basic fibroblast growth factor |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
EP0242216A1 (en) | 1986-04-16 | 1987-10-21 | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce | Non-cytopathic clone of Human T-Cell Lymphotropic Virus type III |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
US4879227A (en) | 1986-05-06 | 1989-11-07 | Genetics Institute, Inc. | Production of a recombinant human colony stimulating factor |
ES2061500T5 (en) | 1986-06-17 | 2003-05-16 | Chiron Corp | DIAGNOSIS AND VACCINES OF DELTA HEPATITIS, ITS PREPARATION AND USE. |
WO1988000471A1 (en) | 1986-07-21 | 1988-01-28 | Southwest Foundation For Biomedical Research | Composition of matter and method of immunizing against viral causative agents of aids and arc |
US5135855A (en) | 1986-09-03 | 1992-08-04 | The United States Of America As Represented By The Department Of Health And Human Services | Rapid, versatile and simple system for expressing genes in eukaryotic cells |
US4861707A (en) | 1987-02-02 | 1989-08-29 | E. I. Du Pont De Nemours And Company | Human immunodeficiency virus antigen |
GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
US4980289A (en) | 1987-04-27 | 1990-12-25 | Wisconsin Alumni Research Foundation | Promoter deficient retroviral vector |
US5256767A (en) | 1987-06-10 | 1993-10-26 | The Immune Response Corporation | Retroviral antigens |
EP0300213A1 (en) | 1987-06-22 | 1989-01-25 | Hexal-Pharma Gentechnik GmbH & Co. KG | Hepatitis a viral peptide particle immunogens |
US5637677A (en) | 1987-07-16 | 1997-06-10 | The Trustees Of The University Of Pennsylvania | Biologically active compounds and methods of constructing and using the same |
US4966852A (en) | 1987-07-23 | 1990-10-30 | Monsanto Company | DNA clone of human tissue factor inhibitor |
US5106833A (en) | 1987-07-23 | 1992-04-21 | Washington University | Coagulation inhibitors |
AU2914889A (en) | 1987-08-28 | 1989-04-17 | Board Of Regents, The University Of Texas System | Prophylaxis and therapy of acquired immunodeficiency syndrome |
US5128319A (en) | 1987-08-28 | 1992-07-07 | Board Of Regents, The University Of Texas System | Prophylaxis and therapy of acquired immunodeficiency syndrome |
DE10399032I1 (en) | 1987-08-28 | 2004-01-29 | Health Research Inc | Recombinant viruses. |
JPH02501192A (en) | 1987-09-04 | 1990-04-26 | バイオジェン インコーポレイテッド | DNA sequences, recombinant DNA molecules and methods for producing soluble T4 protein |
WO1989002468A1 (en) | 1987-09-11 | 1989-03-23 | Whitehead Institute For Biomedical Research | Transduced fibroblasts and uses therefor |
US5879907A (en) | 1987-09-14 | 1999-03-09 | Skandigen Ab | Artificial gene coding for authentic human serum albumin, use thereof and method |
PT88641B (en) | 1987-10-02 | 1993-04-30 | Genentech Inc | METHOD FOR PREPARING A VARIETY OF ADHESION |
IL87902A0 (en) | 1987-10-08 | 1989-03-31 | Dana Farber Cancer Inst Inc | Soluble human cd4 fragments and applications thereof |
US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
US5714596A (en) | 1987-11-18 | 1998-02-03 | Chiron Corporation | NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus |
US5712088A (en) | 1987-11-18 | 1998-01-27 | Chiron Corporation | Methods for detecting Hepatitis C virus using polynucleotides specific for same |
US5683864A (en) | 1987-11-18 | 1997-11-04 | Chiron Corporation | Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies |
WO1989005349A1 (en) | 1987-12-09 | 1989-06-15 | The Australian National University | Method of combating viral infections |
US5179022A (en) | 1988-02-29 | 1993-01-12 | E. I. Du Pont De Nemours & Co. | Biolistic apparatus for delivering substances into cells and tissues in a non-lethal manner |
CN1038306A (en) | 1988-03-21 | 1989-12-27 | 维吉恩公司 | Recombinant retroviruses |
AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
CA1340748C (en) | 1988-07-13 | 1999-09-14 | Stephen Oroszlan | Synthetic hiv protease gene and method for its expression |
CA1339354C (en) | 1988-09-01 | 1997-08-26 | The Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
DE68918867T2 (en) | 1988-09-13 | 1995-02-16 | Chiron Corp | Mutants of the hiv-1 coat protein with missing hypervariable domains. |
AU640619B2 (en) | 1988-10-03 | 1993-09-02 | Repligen Corporation | Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids |
US5997856A (en) | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
CA2003383A1 (en) | 1988-11-23 | 1990-05-23 | Sushil G. Devare | Synthetic dna derived recombinant hiv antigens |
PT92479A (en) | 1988-12-01 | 1990-06-29 | Univ North Carolina | PROCESS OF PREPARATION OF RECOMBINANT GENES AND ITS CODING PROTEINS |
WO1990007936A1 (en) | 1989-01-23 | 1990-07-26 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
US5082767A (en) | 1989-02-27 | 1992-01-21 | Hatfield G Wesley | Codon pair utilization |
IL93682A (en) | 1989-03-16 | 1996-06-18 | Yeda Res & Dev | Polycyclic compounds having antiviral activity their use in the manufacture of medicaments and pharmaceutical compositions containing them |
WO1990011359A1 (en) | 1989-03-20 | 1990-10-04 | Whitehead Institute For Biomedical Research | Intracellular method of inhibiting hiv in mammalian cells |
US6214804B1 (en) | 1989-03-21 | 2001-04-10 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
CA2489769A1 (en) | 1989-03-21 | 1990-10-04 | Philip L. Felgner | Expression of exogenous polynucleotide sequences in a vertebrate |
AU5421090A (en) | 1989-04-05 | 1990-11-05 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | A clone of double-stranded rna virus and applications thereof |
US5691170A (en) * | 1989-04-18 | 1997-11-25 | Therion Biologics | Generation of hybrid genes and proteins by virus-mediated recombination |
CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
EP0431128B1 (en) | 1989-06-01 | 2003-03-26 | Applied Biotechnology, Inc. | Vector coding for self-assembled, defective, non-self-propagating viral particles |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
JP4041535B2 (en) | 1989-08-18 | 2008-01-30 | オックスフォード バイオメディカ(ユーケー)リミテッド | Recombinant retroviruses that carry vector constructs to target cells |
US5240846A (en) | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
GB8919607D0 (en) | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
US5130247A (en) | 1989-09-19 | 1992-07-14 | Merck & Co., Inc. | Expression of fusion protein of HIV envelope and HBsAG |
EP0493508A1 (en) | 1989-09-22 | 1992-07-08 | Idec Pharmaceuticals Corporation | Novel peptides associated with the cd4 binding region of gp120 and their methods of use |
DE69019291T2 (en) | 1989-10-23 | 1995-09-21 | Hoffmann La Roche | Synthetic HTLV-I envelope peptides. |
FR2658432B1 (en) | 1990-02-22 | 1994-07-01 | Medgenix Group Sa | MICROSPHERES FOR THE CONTROLLED RELEASE OF WATER-SOLUBLE SUBSTANCES AND PREPARATION METHOD. |
US5876724A (en) | 1990-03-19 | 1999-03-02 | Institut Pasteur | Induction of neutralizing antibody against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein |
ES2140380T5 (en) | 1990-03-21 | 2005-03-16 | Geneart Gmbh | DNA SEQUENCES CODING MODIFIED RETROVIRIC GAG POLYPEPTIDES AND VACCINES CONTAINING OR ADDED THEMSELVES. |
AU8200191A (en) | 1990-07-09 | 1992-02-04 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | High efficiency packaging of mutant adeno-associated virus using amber suppressions |
WO1992001800A1 (en) | 1990-07-20 | 1992-02-06 | Chiron Corporation | Method for integrative transformation of yeast using dispersed repetitive elements |
MY109299A (en) | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
US5840313A (en) | 1990-09-27 | 1998-11-24 | Syntello Vaccine Development Kb | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus |
GB9021004D0 (en) | 1990-09-27 | 1990-11-07 | Wellcome Found | Acellular vaccines |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
DE69129154T2 (en) | 1990-12-03 | 1998-08-20 | Genentech Inc | METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES |
IE920366A1 (en) | 1991-02-04 | 1992-08-12 | Univ Saskatchewan | Vp6 encapsulated drug delivery |
US5766598A (en) * | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
AU1643692A (en) | 1991-03-07 | 1992-10-06 | Seragen, Inc. | Use of cell surface receptor targeted molecules for the treatment of viral diseases |
IL101715A (en) | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
ATE237694T1 (en) | 1991-08-20 | 2003-05-15 | Us Gov Health & Human Serv | ADENOVIRUS-MEDIATED GENE TRANSFER INTO THE GASTROINTESTINAL TRACT |
WO1994004574A1 (en) | 1991-08-22 | 1994-03-03 | Nissin Shokuhin Kabushiki Kaisha | Hiv immunotherapeutics |
CA2116764C (en) | 1991-09-13 | 1999-12-07 | Amy J. Weiner | Immunoreactive hepatitis c virus polypeptide compositions |
WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
IT1253009B (en) | 1991-12-31 | 1995-07-10 | Sclavo Ricerca S R L | DETOXIFIED IMMUNOGENIC MUTANTS OF COLERIC TOXIN AND TOXIN LT, THEIR PREPARATION AND USE FOR THE PREPARATION OF VACCINES |
US5214804A (en) * | 1992-01-27 | 1993-06-01 | Carey Michael J | Protective mask with scarf |
US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
DK0643585T3 (en) | 1992-06-01 | 2000-05-08 | Chiron Corp | The use of lipoprotein-associated coagulation inhibitor (LACI) in the manufacture of a drug for the treatment of ac |
EP0650370A4 (en) | 1992-06-08 | 1995-11-22 | Univ California | Methods and compositions for targeting specific tissue. |
JPH09507741A (en) | 1992-06-10 | 1997-08-12 | アメリカ合衆国 | Vector particles resistant to inactivation by human serum |
KR950701820A (en) | 1992-06-11 | 1995-05-17 | 로저 에이. 윌리암스 | PROPHYLAXS AND TREATMENT OF SEPSIS AND SEPSIS-ASSOCIATED COAGULATION DISORDERS |
JP3111079B2 (en) | 1992-07-27 | 2000-11-20 | ニューヨーク・ユニバーシティ | Medical high-field magnet |
GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
US5519021A (en) | 1992-08-07 | 1996-05-21 | Merck & Co., Inc. | Benzoxazinones as inhibitors of HIV reverse transcriptase |
DE4228458A1 (en) | 1992-08-27 | 1994-06-01 | Beiersdorf Ag | Multicistronic expression units and their use |
FR2695563B1 (en) | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticles carrying antigens and their use for the induction of humoral or cellular responses. |
US6004763A (en) | 1992-09-11 | 1999-12-21 | Institut Pasteur | Antigen-carrying microparticles and their use in the induction of humoral or cellular responses |
CA2105629A1 (en) | 1992-09-14 | 1994-03-15 | Robert S. Becker | Potentiation of immunogenic response |
US5686078A (en) | 1992-09-14 | 1997-11-11 | Connaught Laboratories, Inc. | Primary and secondary immunization with different physio-chemical forms of antigen |
US5831005A (en) | 1992-09-24 | 1998-11-03 | Chiron Corporation | Synthesis of N-substituted oligomers |
US5304472A (en) | 1992-11-20 | 1994-04-19 | Genentech, Inc. | Method of controlling polypeptide production in bacterial cells |
DK0672142T3 (en) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalent and multi-specific binding proteins as well as their preparation and use |
DE59402827D1 (en) | 1993-01-16 | 1997-06-26 | Manfred Dr Schawaller | METHOD FOR OBTAINING NATIVE, OLIGOMERIC, GLYCOSYLATED EKTODOMÄNEN VIRAL MEMBRANE PROTEINS, THEIR USE, ESPECIALLY AS A VACCINE AGAINST HIV |
US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
US5869624A (en) * | 1993-03-26 | 1999-02-09 | Progenics Pharmaceuticals, Inc. | HIV-1 vaccines, antibody compositions related thereto, and therapeutic and prophylactic uses thereof |
KR100325554B1 (en) | 1993-03-26 | 2002-11-02 | 젠-프로브 인코포레이티드 | Detection of Human Immunodeficiency Virus Type 1 |
US5591601A (en) | 1993-05-14 | 1997-01-07 | Ohio University Edison Animal Biotechnology Institute | DNA polymerase gene expression system utilizing an RNA polymerase co-delivered with the gene expression vector system |
US5419900A (en) | 1993-05-19 | 1995-05-30 | The United States Of America As Represented By The Department Of Of Health And Human Services | Immunologic enhancement with intermittent interleukin-2 therapy |
EP0708659A4 (en) | 1993-06-07 | 2000-08-23 | Genentech Inc | Hiv envelope polypeptides |
AU693098B2 (en) | 1993-06-09 | 1998-06-25 | Connaught Laboratories Limited | Tandem synthetic HIV-1 peptides |
US5614413A (en) | 1993-07-01 | 1997-03-25 | The Uab Research Foundation | Encapsidated recombinant poliovirus nucleic acid and methods of making and using same |
US5834441A (en) | 1993-09-13 | 1998-11-10 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Adeno-associated viral (AAV) liposomes and methods related thereto |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
JPH0786988A (en) * | 1993-09-16 | 1995-03-31 | Fujitsu Ltd | Device and method for pca transmission |
WO1995013376A1 (en) | 1993-11-10 | 1995-05-18 | Amgen Inc. | Gene therapy vector for the treatment of low or defective red blood cell production |
EP0755268A1 (en) | 1994-04-11 | 1997-01-29 | Baylor College Of Medicine | Compositions and methods for gene therapy to treat disease |
US6291157B1 (en) | 1998-02-23 | 2001-09-18 | Connaught Laboratories Limited | Antigenically-marked non-infectious retrovirus-like particles |
US5955342A (en) | 1994-08-15 | 1999-09-21 | Connaught Laboratories Limited | Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US6080408A (en) | 1994-08-22 | 2000-06-27 | Connaught Laboratories Limited | Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles |
US5648331A (en) | 1994-08-26 | 1997-07-15 | G.D. Searle & Co. | Method of inhibiting tissue ischemia and reperfusion injury |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
US5795737A (en) | 1994-09-19 | 1998-08-18 | The General Hospital Corporation | High level expression of proteins |
US5676950A (en) | 1994-10-28 | 1997-10-14 | University Of Florida | Enterically administered recombinant poxvirus vaccines |
US5550280A (en) | 1994-11-30 | 1996-08-27 | Uniroyal Chemical Ltd./ Uniroyal Chemical Ltee | Hindered aromatic ester compounds useful as anti-viral agents |
AU4594996A (en) | 1994-11-30 | 1996-06-19 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
DK0800579T3 (en) | 1994-12-30 | 2002-09-09 | Chiron Corp | Combinatorial gene delivery vehicles |
US5681746A (en) | 1994-12-30 | 1997-10-28 | Chiron Viagene, Inc. | Retroviral delivery of full length factor VIII |
EP0817854A2 (en) | 1995-03-31 | 1998-01-14 | Wolf, Hans, Prof. Dr. | Antigen presentation system based on retrovirus-like particles |
AU6455896A (en) | 1995-07-11 | 1997-02-10 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered metal-binding properties |
WO1997003195A1 (en) | 1995-07-11 | 1997-01-30 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered protease sites |
WO1997003194A1 (en) | 1995-07-11 | 1997-01-30 | Chiron Corporation | Lysine 1689 factor viii:c polypeptide analogs |
AU6291896A (en) | 1995-07-11 | 1997-02-10 | Chiron Corporation | Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains |
US5766464A (en) * | 1995-11-22 | 1998-06-16 | Campbell; David C. | Fluid filtration system positionable within a fluid-containing apparatus |
CU22559A1 (en) | 1996-01-17 | 1999-05-03 | Ct Ingenieria Genetica Biotech | EXPRESSION SYSTEM OF HETEROLOGICAL ANTIGENS IN E. COLI AS FUSION PROTEINS |
US5741492A (en) | 1996-01-23 | 1998-04-21 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
US6087486A (en) | 1996-01-29 | 2000-07-11 | The Trustees Of The University Of Pennsylvania | Nucleotide sequences encoding vpr receptor protein |
US6060587A (en) | 1996-01-29 | 2000-05-09 | The Trustees Of The University Of Pennsylvania | Cellular receptor for HIV-1 VPR essential for G2/M phase transition of the cell cycle |
EP1997900A3 (en) | 1996-04-05 | 2010-10-06 | Novartis Vaccines and Diagnostics, Inc. | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
US5951975A (en) | 1996-06-28 | 1999-09-14 | University Of Pittsburgh | Induction of CTLs specific for natural antigens by cross priming immunization |
AU4181897A (en) | 1996-09-06 | 1998-03-26 | Regents Of The University Of California, The | E25a protein, methods for production and use thereof |
US6139833A (en) | 1997-08-08 | 2000-10-31 | Lexicon Genetics Incorporated | Targeted gene discovery |
US5858675A (en) | 1997-05-13 | 1999-01-12 | Incyte Pharmaceuticals, Inc. | Double-stranded RNA-binding protein |
US6099847A (en) | 1997-05-15 | 2000-08-08 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric Gag pseudovirions |
US5932442A (en) | 1997-09-23 | 1999-08-03 | Incyte Pharmaceuticals, Inc. | Human regulatory molecules |
US5932445A (en) | 1997-11-07 | 1999-08-03 | Incyte Pharmaceuticals, Inc. | Signal peptide-containing proteins |
US6090368A (en) * | 1998-03-03 | 2000-07-18 | The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations | Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine |
JP2002511257A (en) | 1998-04-14 | 2002-04-16 | カイロン コーポレイション | Non-cloning technology for expressing the gene of interest |
US6090388A (en) | 1998-06-20 | 2000-07-18 | United Biomedical Inc. | Peptide composition for prevention and treatment of HIV infection and immune disorders |
US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
EP1165798A2 (en) * | 1999-03-29 | 2002-01-02 | Statens Serum Institut | Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope |
JP2003513635A (en) | 1999-11-01 | 2003-04-15 | カイロン コーポレイション | Expression vectors, transfection systems, and methods of using them |
CA2634992C (en) | 2001-07-05 | 2012-10-16 | Novartis Vaccines And Diagnostics, Inc. | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
US7800921B2 (en) | 2007-01-08 | 2010-09-21 | Continental Automotive Systems Us, Inc. | DC/DC converter |
EP2510962A1 (en) | 2011-04-12 | 2012-10-17 | F. Hoffmann-La Roche AG | Infusion pump device with re-filling scheme for cylinder-piston dosing unit |
-
1999
- 1999-12-30 AU AU22216/00A patent/AU2221600A/en not_active Abandoned
- 1999-12-30 EP EP10003431A patent/EP2206785A1/en not_active Withdrawn
- 1999-12-30 JP JP2000591193A patent/JP2002533124A/en active Pending
- 1999-12-30 WO PCT/US1999/031245 patent/WO2000039302A2/en not_active Application Discontinuation
- 1999-12-30 CA CA2360347A patent/CA2360347C/en not_active Expired - Fee Related
- 1999-12-30 US US09/475,515 patent/US6602705B1/en not_active Expired - Lifetime
- 1999-12-30 EP EP99966727A patent/EP1141313A2/en not_active Withdrawn
- 1999-12-30 EP EP07075871A patent/EP1980617A1/en not_active Withdrawn
-
2003
- 2003-03-11 US US10/387,336 patent/US7348177B2/en not_active Expired - Fee Related
-
2008
- 2008-02-06 US US12/026,619 patent/US7718401B2/en not_active Expired - Fee Related
-
2010
- 2010-04-30 US US12/770,905 patent/US8168418B2/en not_active Expired - Lifetime
- 2010-10-18 JP JP2010234059A patent/JP2011019534A/en active Pending
-
2011
- 2011-06-01 JP JP2011123833A patent/JP2011172593A/en active Pending
-
2012
- 2012-04-27 US US13/458,232 patent/US20120269840A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997031115A2 (en) * | 1996-02-22 | 1997-08-28 | Merck & Co., Inc. | Synthetic hiv genes |
WO1998012207A1 (en) * | 1996-09-20 | 1998-03-26 | The General Hospital Corporation | High level expression of proteins |
WO1998034640A2 (en) * | 1997-02-07 | 1998-08-13 | Merck & Co., Inc. | Synthetic hiv gag genes |
WO1999041397A1 (en) * | 1998-02-17 | 1999-08-19 | Oxford Biomedica (Uk) Limited | Anti-viral vectors |
WO2000015819A1 (en) * | 1998-09-11 | 2000-03-23 | The Children's Medical Center Corporation | Packaging cell lines for hiv-derived retroviral vector particles |
Non-Patent Citations (4)
Title |
---|
ANDRE S ET AL: "INCREASED IMMUNE RESPONSE ELICITED BY DNA VACCINATION WITH A SYNTHETIC GP120 SEQUENCE WITH OPTIMIZED CODON USAGE", JOURNAL OF VIROLOGY,US,THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 72, no. 2, 1 February 1998 (1998-02-01), pages 1497 - 1503, XP002073767, ISSN: 0022-538X * |
LU S ET AL: "IMMUNOGENICITY OF DNA VACCINES EXPRESSING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 ENVELOPE GLYCOPROTEIN WITH AND WITHOUT DELETIONS IN THE V1/2 AND V3 REGIONS", AIDS RESEARCH AND HUMAN RETROVIRUSES,US,MARY ANN LIEBERT, vol. 14, no. 2, 20 January 1998 (1998-01-20), pages 151 - 155, XP000907375, ISSN: 0889-2229 * |
SCHNEIDER R ET AL: "Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows rev-independent expression of gag and gag/protease and particle formation", JOURNAL OF VIROLOGY, vol. 71, no. 7, July 1997 (1997-07-01), AMERICAN SOCIETY FOR MICROBIOLOGY US, pages 4892 - 4903, XP002137891 * |
STAMATATOS L AND CHENG-MAYER C: "An envelope modification that renders a primary, neutralization-resistant clade B HIV-1 isolate highly susceptible to neutralization by sera from other clades", JOURNAL OF VIROLOGY, vol. 72, no. 10, October 1998 (1998-10-01), AMERICAN SOCIETY FOR MICROBIOLOGY US, pages 7840 - 7845, XP002139602 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9598469B2 (en) | 2001-07-05 | 2017-03-21 | Novartis Vaccines And Diagnostics, Inc. | HIV-1 south african subtype C env proteins |
Also Published As
Publication number | Publication date |
---|---|
CA2360347A1 (en) | 2000-07-06 |
US20080261271A1 (en) | 2008-10-23 |
EP1980617A1 (en) | 2008-10-15 |
US7348177B2 (en) | 2008-03-25 |
JP2002533124A (en) | 2002-10-08 |
JP2011019534A (en) | 2011-02-03 |
US8168418B2 (en) | 2012-05-01 |
EP2206785A1 (en) | 2010-07-14 |
JP2011172593A (en) | 2011-09-08 |
US6602705B1 (en) | 2003-08-05 |
US20120269840A1 (en) | 2012-10-25 |
WO2000039302A2 (en) | 2000-07-06 |
US7718401B2 (en) | 2010-05-18 |
EP1141313A2 (en) | 2001-10-10 |
CA2360347C (en) | 2013-05-07 |
US20110065146A1 (en) | 2011-03-17 |
US20030223964A1 (en) | 2003-12-04 |
AU2221600A (en) | 2000-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000039302A3 (en) | Improved expression of hiv polypeptides and production of virus-like particles | |
WO2000039304A3 (en) | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof | |
ATE70308T1 (en) | HYBRID PARTICLE IMMUNOGENS. | |
EP2311958A3 (en) | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof | |
JP2012010713A (en) | Papilloma virus-like particle, fusion protein as well as process for their production | |
KR890701742A (en) | Heterologous Peptide Particle Immunogen | |
CA2020668A1 (en) | Fused or hybrid protein comprising viral antigen and lymphokine | |
JP2001512748A5 (en) | ||
EP0434713A4 (en) | Hiv-1 envelope muteins lacking hypervariable domains | |
CA2013582A1 (en) | Method for enhancing transmembrane transport of exogenous molecules | |
EP0757099A3 (en) | CTLA4 mutant molecules and uses thereof | |
AU9052891A (en) | Proteins with changed epitopes and methods for the production thereof | |
WO2000054802A3 (en) | Method of expressing antigens on the surface of antigen presenting cells by photochemical internalization | |
AU4940096A (en) | Host cell expressing reduced levels of a metalloprotease and methods using the host cell in protein production | |
WO2001072277A3 (en) | Immunotherapeutic methods and compositions | |
EP0272858A3 (en) | Recombinant hiv envelope proteins produced in insect cells | |
HK140095A (en) | Hepatitis surface antigen particle vaccine | |
WO2004033627A3 (en) | Methods for efficient production of mammalian recombinant proteins | |
EP1433851A3 (en) | Improved expression of HIV polypeptides and production of virus-like particles | |
DE68907735T2 (en) | Gene fragments encoding the variable region of an anti-HIV antibody, chimeric anti-HIV antibodies expressed therefrom, and methods for their production. | |
CA2084386A1 (en) | Hiv antigen | |
EP0400569A3 (en) | Method for preparing a vaccine from Streptococcus mutans for dental caries and vaccinal compositions for dental caries used as nasal drops | |
JP2002522039A5 (en) | ||
WO2001059073A3 (en) | Cytotoxic t lymphocytes activated by dendritic cell hybrids | |
CA2324649A1 (en) | Human p51 genes and gene products thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref document number: 2000 591193 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/05589 Country of ref document: ZA Ref document number: 200105589 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999966727 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2001/771/KOL Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2360347 Country of ref document: CA Ref document number: 2360347 Country of ref document: CA Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1999966727 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999966727 Country of ref document: EP |